Thomas Harding - 01 Jul 2022 Form 4 Insider Report for Clovis Oncology, Inc.

Role: Senior Vice President and Chief Scientific Officer
Signature: /s/ Thomas Harding
Issuer symbol: N/A
Transactions as of: 01 Jul 2022
Net transactions value: -$18.97
Form type: 4
Filing time: 06 Jul 2022, 16:15:15 UTC
Previous filing: 03 Jun 2022
Next filing: 03 Aug 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CLVS	Common Stock	Options Exercise		+16	+0.5%		3,241	01 Jul 2022	By wife	F1
transaction	CLVS	Common Stock	Sale	$18.97	-7	-0.22%	$2.71^*	3,234	05 Jul 2022	By wife	F2
holding	CLVS	Common Stock						14,720	01 Jul 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CLVS	Restricted Stock Units	Options Exercise	$0	-16	-11%	$0.000000	124	01 Jul 2022	Common Stock	16		By wife	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit represents the right to receive one share of Common Stock.
F2	Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3	On July 1, 2020, the reporting person's wife was granted 250 Restricted Stock Units. 25% of such Restricted Stock Units vested on July 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

Remarks:

Senior Vice President and Chief Scientific Officer